X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Aventis Pharma with Glenmark Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

SANOFI INDIA vs GLENMARK PHARMA - Comparison Results

SANOFI INDIA    Change

Sanofi India (the erstwhile Aventis Pharma), the 60% subsidiary of Sanofi-Aventis SA, France, is one of the largest pharma MNCs in India with a turnover of over Rs 13.2 bn in CY11. Domestic sales constituted 81% of total sales in CY11 and exports con... More

GLENMARK PHARMA 
   Change

Glenmark's focus areas are dermatology, gynecology, pediatrics and diabetics. The domestic formulations business contributed about 35% to revenues in FY07. On the international front, besides exports to the semi-regulated markets, the company has bee... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    SANOFI INDIA GLENMARK PHARMA SANOFI INDIA/
GLENMARK PHARMA
 
P/E (TTM) x 34.3 20.2 169.5% View Chart
P/BV x 6.9 3.6 190.2% View Chart
Dividend Yield % 1.3 0.3 392.9%  

Financials

 SANOFI INDIA   GLENMARK PHARMA
EQUITY SHARE DATA
    SANOFI INDIA
Dec-16
GLENMARK PHARMA
Mar-17
SANOFI INDIA/
GLENMARK PHARMA
5-Yr Chart
Click to enlarge
High Rs4,560993 459.2%   
Low Rs4,400729 603.3%   
Sales per share (Unadj.) Rs1,028.5325.5 315.9%  
Earnings per share (Unadj.) Rs129.039.3 328.2%  
Cash flow per share (Unadj.) Rs186.048.7 382.2%  
Dividends per share (Unadj.) Rs68.002.00 3,400.0%  
Dividend yield (eoy) %1.50.2 653.6%  
Book value per share (Unadj.) Rs753.6159.2 473.3%  
Shares outstanding (eoy) m23.03282.17 8.2%   
Bonus/Rights/Conversions -ESOP-  
Price / Sales ratio x4.42.6 164.7%   
Avg P/E ratio x34.721.9 158.5%  
P/CF ratio (eoy) x24.117.7 136.1%  
Price / Book Value ratio x5.95.4 109.9%  
Dividend payout %52.75.1 1,036.0%   
Avg Mkt Cap Rs m103,174242,991 42.5%   
No. of employees `0003.613.0 27.9%   
Total wages/salary Rs m3,59216,408 21.9%   
Avg. sales/employee Rs Th6,537.77,083.9 92.3%   
Avg. wages/employee Rs Th991.41,265.4 78.4%   
Avg. net profit/employee Rs Th819.8855.1 95.9%   
INCOME DATA
Net Sales Rs m23,68691,857 25.8%  
Other income Rs m708374 189.5%   
Total revenues Rs m24,39492,230 26.4%   
Gross profit Rs m5,28120,367 25.9%  
Depreciation Rs m1,3132,644 49.7%   
Interest Rs m152,373 0.6%   
Profit before tax Rs m4,66115,724 29.6%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m0-810 0.0%   
Tax Rs m1,6913,827 44.2%   
Profit after tax Rs m2,97011,088 26.8%  
Gross profit margin %22.322.2 100.6%  
Effective tax rate %36.324.3 149.1%   
Net profit margin %12.512.1 103.9%  
BALANCE SHEET DATA
Current assets Rs m15,67368,746 22.8%   
Current liabilities Rs m6,67827,027 24.7%   
Net working cap to sales %38.045.4 83.6%  
Current ratio x2.32.5 92.3%  
Inventory Days Days7685 89.4%  
Debtors Days Days2296 23.4%  
Net fixed assets Rs m8,09824,132 33.6%   
Share capital Rs m230282 81.6%   
"Free" reserves Rs m17,08844,643 38.3%   
Net worth Rs m17,35644,925 38.6%   
Long term debt Rs m045,363 0.0%   
Total assets Rs m25,400117,639 21.6%  
Interest coverage x311.77.6 4,088.0%   
Debt to equity ratio x01.0 0.0%  
Sales to assets ratio x0.90.8 119.4%   
Return on assets %11.811.4 102.7%  
Return on equity %17.124.7 69.3%  
Return on capital %26.919.1 140.7%  
Exports to sales %24.50-   
Imports to sales %28.00-   
Exports (fob) Rs m5,801NA-   
Imports (cif) Rs m6,627NA-   
Fx inflow Rs m7,14556,152 12.7%   
Fx outflow Rs m6,8468,084 84.7%   
Net fx Rs m29948,068 0.6%   
CASH FLOW
From Operations Rs m3,2266,574 49.1%  
From Investments Rs m-1,555-7,124 21.8%  
From Financial Activity Rs m-1,8185,432 -33.5%  
Net Cashflow Rs m-1471,992 -7.4%  

Share Holding

Indian Promoters % 0.0 48.3 -  
Foreign collaborators % 60.4 0.0 -  
Indian inst/Mut Fund % 14.4 6.9 208.7%  
FIIs % 14.6 34.4 42.4%  
ADR/GDR % 0.0 0.0 -  
Free float % 10.5 10.5 100.0%  
Shareholders   15,184 56,727 26.8%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare SANOFI INDIA With:   ALEMBIC PHARMA  FRESENIUS KABI ONCO.  TTK HEALTHCARE  ASTRAZENECA PHARMA  DISHMAN PHARMA  

Compare SANOFI INDIA With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends Day up 260 Points; Pharma Stocks Top Gainers(Closing)

After opening the day in red, share markets in India witnessed positive trading activity throughout the day and ended the day on a positive note.

Related Views on News

GLENMARK PHARMA Announces Quarterly Results (4QFY18); Net Profit Down 6.6%

May 31, 2018 | Updated on May 31, 2018

For the quarter ended March 2018, GLENMARK PHARMA has posted a net profit of Rs 2 bn (down 6.6% YoY). Sales on the other hand came in at Rs 23 bn (down 7.2% YoY). Read on for a complete analysis of GLENMARK PHARMA's quarterly results.

Glenmark: Most Geographies Show Weak Growth (Quarterly Results Update - Detailed)

Nov 7, 2017

Poor show in the US, Latam and India hit profits during the quarter.

Glenmark: Zetia Bolsters Sales and Profits (Quarterly Results Update - Detailed)

Oct 30, 2017

The 180-day exclusivity for Zetia enabled Glenmark to show strong growth in sales and profits during the quarter.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

More Views on News

Most Popular

Alert: Pharma Stocks Are About to Shoot Up - And a Superb Stock for Trading(Profit Hunter)

Jun 13, 2018

The ailing pharma stocks are bouncing back to health. Read this to find out the best way to profit from them.

Will You Dump Your Client if You're Busy? Inox Wind's Auditor Just Did...(The 5 Minute Wrapup)

Jun 14, 2018

After Inox Wind, you may see more auditors resigning And the reasons can be as funny as they can get.

GST Will Not Solve Problem of High Prices of Petrol and Diesel(Vivek Kaul's Diary)

Jun 13, 2018

Though it will bring transparency in their pricing and that in itself will be a welcome move.

Should You Invest In Mirae Asset Healthcare Fund?(Outside View)

Jun 15, 2018

Mirae Asset Mutual Fund launches NFO - Mirae Asset Helathcare Fund.

Has the Market Bottomed Out?(Sector Info)

Jun 11, 2018

The yield spread is an effective barometer that can indicate the direction the markets are headed.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

SANOFI INDIA SHARE PRICE


Jun 22, 2018 (Close)

TRACK SANOFI INDIA

  • Track your investment in SANOFI INDIA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

SANOFI INDIA 5-YR ANALYSIS

COMPARE SANOFI INDIA WITH

MARKET STATS